Literature DB >> 34538616

Medical therapy of HCC.

Arndt Vogel1, Anna Saborowski2.   

Abstract

Entities:  

Keywords:  VEGF; hepatocellular carcinoma; immunotherapy; molecular therapy; targeted therapies; tyrosine kinase inhibitor

Mesh：

Year:  2021        PMID： 34538616     DOI： 10.1016/j.jhep.2021.05.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

1.  Application Effect of ICG Fluorescence Real-Time Imaging Technology in Laparoscopic Hepatectomy.

Authors:  Hao Chen; Yumin Wang; Zhiguo Xie; Luyuan Zhang; Yongsheng Ge; Jihai Yu; Chuanhai Zhang; Weidong Jia; Jinliang Ma; Wenbin Liu
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

2.  Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients.

Authors:  Katsuya Toshida; Shinji Itoh; Takahiro Tomiyama; Akinari Morinaga; Yukiko Kosai; Takahiro Tomino; Takeshi Kurihara; Yoshihiro Nagao; Kazutoyo Morita; Noboru Harada; Tomoharu Yoshizumi
Journal:  JGH Open       Date:  2022-06-08

3.  Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.

Authors:  Jie Fu; Xiaohua Lei
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

4.  Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma.

Authors:  Zhihao Yang; Yaoshu Song; Ya Li; Yiming Mao; Guobo Du; Bangxian Tan; Hongpan Zhang
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.